Regeneron and Sanofi's Dupixent (dupilumab) Receive the US FDA's Approval as an Add-On Maintenance Treatment to Treat Moderate-To-Severe Asthma
Shots:
- The P-III LIBERTY ASTHMA VOYAGE Trial evaluates Dupixent (100/200mg- q2w) + SoC in 408 children aged 6-11yrs. with uncontrolled mod. to sev. asthma
- The results showed a 65% avg. reduction in the rate of severe asthma attacks @1yrs.; improvement in lung function by 5.32% points @ 12wks. & as early as 2wks. & sustained for ~52wks- improved asthma control @24wks.; improvement on disease symptoms & impact (81% vs 64%) as measured by ≥0.5 improvements on a 7-point scale
- The safety results were consistent with the known safety profile of Dupixent in patients aged ≥12yrs. The therapy is currently under regulatory review in the EU & other authorities globally for children aged 6 to 11yrs.
click here | Ref: PRNewswire| Image: Sanofi
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
